|
NME7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.7715611723761E-16 |
| Normal-vs-Stage2 |
7.82189979453563E-10 |
| Normal-vs-Stage3 |
4.42978986825437E-14 |
| Normal-vs-Stage4 |
1.63680180520487E-12 |
| Stage1-vs-Stage2 |
5.839200E-01 |
| Stage1-vs-Stage3 |
5.540200E-01 |
| Stage1-vs-Stage4 |
2.414300E-02 |
| Stage2-vs-Stage3 |
9.122000E-01 |
| Stage2-vs-Stage4 |
3.020600E-01 |
| Stage3-vs-Stage4 |
1.376560E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.363870E-04 |
| Normal-vs-Asian |
1.20980003792681E-10 |
| Caucasian-vs-AfricanAmerican |
1.206000E-01 |
| Caucasian-vs-Asian |
8.964200E-01 |
| AfricanAmerican-vs-Asian |
1.972980E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.62883073484954E-14 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
3.800800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
1.35114142096882E-13 |
| Normal-vs-Age(61-80Yrs) |
1.75914838251856E-12 |
| Normal-vs-Age(81-100Yrs) |
4.018500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.235400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.032200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.491400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.492240E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.047800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.684400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.323600E-03 |
| Classical-VS-Follicular |
3.772200E-02 |
| Classical-VS-Other |
5.929800E-01 |
| Classical-VS-Normal |
1.62481139653892E-12 |
| Tall-VS-Follicular |
5.037600E-01 |
| Tall-VS-Other |
6.839600E-01 |
| Tall-VS-Normal |
2.10165218561542E-13 |
| Follicular-VS-Other |
8.320000E-01 |
| Follicular-VS-Normal |
2.06679118264219E-12 |
| Other-VS-Normal |
1.238900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.88737914186277E-15 |
| Normal-vs-N1 |
1.01474384450739E-13 |
| N0-vs-N1 |
1.612190E-01 |
|
|
